Back To Search | Back To Preliminary View | Home

A Phase I, Open-Label, Dose Escalation Study of Daily Dosing with BB-10901. Pancreatica Trial ID: PA-7558 Trial Phase Alternative Drug Names Phase 1 Disease Stage (least advanced) Tumor Type Advanced Neuroendocrine tumor (e.g. islet-cell tumor) Treatment Immunotherapy (includes vaccines) Drug and Trial Classifications and Mechanisms monoclonal antibody Special Inclusion Criteria -Not Specified- Main Exclusion Criteria Liver / kidney function requirements? Yes Activity status requirements? Yes Prior Therapy Allowed? Chemo or Biological? Selectively Allowed Radiation? Selectively Allowed Surgery? Selectively Allowed Other? Not Specified Treatment Interval 16 to 31 days Bibliography If you would like to find information about the drug-agents in this trial or about related studies, please consider searches using the following tools: MEDLINE / PubMed http://www.ncbi.nlm.nih.gov/PubMed ASCO Abstracts http://www.asco.org/ Google http://www.google.com Sponsors PDQ Protocol Summary Institutions Baystate Regional Cancer Program Springfield, MA, US Ohio State University Columbus, OH, US M.D. Anderson Cancer Center, University of Texas Houston, TX, US Christie Hospital N.H.S. Trust Manchester , England Cancer Research Centre at Weston Park Hospital Sheffield, England Royal Marsden Hospital Sutton, Surrey, England